Alpha 2.0
Login Register
» Authors » Sylvain Fouliard

Sylvain Fouliard

Explore the profile of Sylvain Fouliard including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 354
Followers 0
Related Specialties
Pharmacology
Oncology
General Medicine
Top 10 Co-Authors
Marylore Chenel
Ibtissam Marchiq
Sandra Dupouy
Donald E Mager
Thibaud Derippe
Maria Almena-Carrasco
Agnieszka Jozwik
Marcela V Maus
Glenn Gauderat
Nicolas Boissel
Published In
J Pharmacokinet Pharmacodyn
AAPS J
CPT Pharmacometrics Syst Pharmacol
Clin Pharmacol Ther
Cancer Res Commun
Affiliations
Soon will be listed here.
Recent Articles
1.
Virtual patients inspired by multiomics predict the efficacy of an anti-IFNα mAb in cutaneous lupus
Hurez V, Gauderat G, Soret P, Myers R, Dasika K, Sheehan R, et al.
iScience . 2025 Feb; 28(2):111754. PMID: 39925417
Lupus erythematosus is a heterogeneous autoimmune disease that requires treatments tailored to specific patient subsets. To evaluate the efficacy of the anti-IFNα S95021 monoclonal antibody, we created a quantitative systems...
2.
Quantitative systems pharmacology modeling of tumor heterogeneity in response to BH3-mimetics using virtual tumors calibrated with cell viability assays
Derippe T, Fouliard S, Decleves X, Mager D
CPT Pharmacometrics Syst Pharmacol . 2024 May; 13(7):1252-1263. PMID: 38747730
Both primary and acquired resistance mechanisms that involve intra-tumoral cell heterogeneity limit the use of BH3-mimetics to trigger tumor cell apoptosis. This article proposes a new quantitative systems pharmacology (QSP)-based...
3.
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, et al.
Cancer Res Commun . 2023 Mar; 2(11):1520-1531. PMID: 36970059
Background: UCART19 is an "off-the-shelf" genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells. Methods: UCART19 was administered to 25 adult patients with relapsed or...
4.
Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia
Derippe T, Fouliard S, Marchiq I, Dupouy S, Almena-Carrasco M, Geronimi J, et al.
Cancer Res Commun . 2023 Mar; 2(11):1532-1544. PMID: 36970053
Significance: A mathematical mechanistic pharmacokinetic/pharmacodynamic model supports and captures quantitatively the beneficial impact of lymphodepleting patients before the infusion of an allogeneic CAR-T cell product. Mediation through IL-7 increase and...
5.
Accelerating robust plausible virtual patient cohort generation by substituting ODE simulations with parameter space mapping
Derippe T, Fouliard S, Decleves X, Mager D
J Pharmacokinet Pharmacodyn . 2022 Nov; 49(6):625-644. PMID: 36316606
The generation of plausible virtual patients (VPs) is an important step in most quantitative systems pharmacology (QSP) workflows, which requires time-intensive solving of ordinary differential equations (ODEs). However, non-physiological profiles...
6.
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Benjamin R, Jain N, Maus M, Boissel N, Graham C, Jozwik A, et al.
Lancet Haematol . 2022 Oct; 9(11):e833-e843. PMID: 36228643
Background: The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors...
7.
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example
Meyer C, Dierick I, Gauderat G, Langenhorst J, Sarr C, Leroux E, et al.
Clin Pharmacol Ther . 2022 Mar; 113(2):310-320. PMID: 35355254
During development of a drug, the requirement of evaluating the proarrhythmic risk and delayed repolarization needs to be fulfilled. Would it be possible to create an alternative to a thorough...
8.
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach
Tosca E, Gauderat G, Fouliard S, Burbridge M, Chenel M, Magni P
CPT Pharmacometrics Syst Pharmacol . 2021 Oct; 10(11):1396-1411. PMID: 34708556
MET receptor tyrosine kinase inhibitors (TKIs) can restore sensitivity to gefitinib, a TKI targeting epidermal growth factor receptor (EGFR), and promote apoptosis in non-small cell lung cancer (NSCLC) models resistant...
9.
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar O, Lucchini G, et al.
Lancet . 2020 Dec; 396(10266):1885-1894. PMID: 33308471
Background: Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical use, thereby broadening access and applicability....
10.
Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm
Chelliah V, Lazarou G, Bhatnagar S, Gibbs J, Nijsen M, Ray A, et al.
Clin Pharmacol Ther . 2020 Jul; 109(3):605-618. PMID: 32686076
Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno-oncology (IO) the aim is to direct the patient's...